Kayyem Jon Faiz
SEC Form 4 insider trading activity
Kayyem Jon Faiz has filed 3 SEC Form 4 filings (3 transaction rows) across 1 company, with disclosures dating back to 2026. 3 of those filings fall inside the rolling window. Most recent filing: Sep 23, 2026.
On the most recent filing, Kayyem Jon Faiz is listed as Director at Inhibrx Biosciences, Inc. Inside the rolling window, Kayyem Jon Faiz reported 3 open-market purchases totaling $1.6M in INBX and no open-market sales. The largest disclosed transaction in the window is a purchase of 5,000 INBX shares on Sep 8, 2026, worth $568K.
Companies traded
Other insiders at INBX
Insider Buying
$1.6M
reported purchases (SEC code P)
Insider Selling
$0
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Kayyem Jon Faiz made?
Kayyem Jon Faiz has filed 3 SEC Form 4 filings (3 transaction rows) across 1 company since 2026.
Which companies does Kayyem Jon Faiz trade?
Kayyem Jon Faiz has filed SEC Form 4 disclosures for 1 company, including INBX.
When was Kayyem Jon Faiz's most recent SEC Form 4 filing?
Kayyem Jon Faiz's most recent SEC Form 4 filing on Tracefour is dated Sep 23, 2026.
What is Kayyem Jon Faiz's total buy and sell value in the current window?
Inside the rolling retention window, Kayyem Jon Faiz bought $1.6M and sold $0 based on SEC Form 4 filings.
What was Kayyem Jon Faiz's largest disclosed transaction?
The largest disclosed transaction in the current window is a purchase of 5,000 INBX shares on 2026-09-08, worth $568K, per SEC Form 4 filings.